MoonLake Immunotherapeutics' CFO Sells 39K Shares
This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.
Overview
On June 22, Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (NASDAQ:MLTX), sold 39,120 common shares in an open-market transaction valued at approximately $862,000, as disclosed in the SEC Form 4 filing.
Transaction value based on SEC Form 4 reported price ($22.04); post-transaction value based on June 22 market close ($22.16).
Details
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on novel immunotherapeutic solutions for inflammatory diseases. The company leverages its proprietary Nanobody platform to address significant unmet medical needs in immunology. Its strategy centers on advancing differentiated assets through clinical development to build a competitive edge in the inflammatory disease market.
Source
Originally published at www.fool.com.